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Abstract
Purpose Everolimus treatment is seriously hampered by its toxicity profile. As a relationship between everolimus exposure and
effectiveness and toxicity has been established, early and ongoing concentration measurement can be key to individualize the
dose and optimize treatment outcomes. Dried blood spot (DBS) facilitates sampling at a patients’ home and thereby eases dose
individualization. The aim of this study is to determine the agreement and predictive performance of DBS compared to whole
blood (WB) to measure everolimus concentrations in cancer patients.
Methods Paired DBS and WB samples were collected in 22 cancer patients treated with everolimus and analyzed using UPLC-
MS/MS. Bland-Altman and Passing-Bablok analysis were used to determine method agreement. Limits of clinical relevance
were set at a difference of ± 25%, as this would lead to a different dosing advice. Using DBS concentration and Passing-Bablok
regression analysis, WB concentrations were predicted.
Results Samples of 20 patients were suitable for analysis. Bland-Altman analysis showed a mean ratio of everolimusWB toDBS
concentrations of 0.90, with 95% of data points within limits of clinical relevance. Passing-Bablok regression of DBS compared
to WB revealed no constant bias (intercept 0.02; 95% CI 0.93–1.35) and a small proportional bias (slope 0.89; 95% CI 0.76–
0.99). Predicted concentrations showed low bias and imprecision and 90% of samples had an absolute percentage prediction error
of < 20%.
Conclusions DBS is a valid method to determine everolimus concentrations in cancer patients. This can especially be of value for
early recognition of over- or underexposure to enable dose adaptations.
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Introduction
The introduction of everolimus has brought significant benefit
for patients with metastatic renal cell carcinoma (mRCC),
metastatic HR+/HER2-breast cancer (mBC), and advanced
or unresectable neuroendocrine tumors of pancreatic, gastro-
intestinal, or lung origin [1–4]. Currently, the treatment with
everolimus in patients with cancer is not individualized and no
therapeutic drug monitoring (TDM) is routinely being per-
formed. The standard initial dose is 10 mg orally once daily,
which may be reduced in case of toxicity or fragility [5]. This
practice is in contrast to solid organ transplantation medicine,
where doses of 0.75 to 1.0 mg twice daily are used and where
TDM of everolimus, including dried blood spot (DBS) mon-
itoring, to guide dosing has been incorporated in the standard
care for over 10 years [6, 7]. Also, everolimus treatment of
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subependymal giant cell astrocytoma with tuberous sclerosis
complex is individualized based on TDM [8].
Several arguments point to the use of TDM for everolimus
in patients with cancer as well. A relationship between evero-
limus drug exposure and effectiveness and safety has been
established in several studies [9–12]. Everolimus trough con-
centrations above 11.9 μg/L and below 26.3 μg/L, respective-
ly, were associated with a threefold increase in progression-
free survival and a fourfold decreased risk of toxicity in pa-
tients with breast cancer, kidney cancer, and neuroendocrine
cancer [10]. Larger studies are required to further define the
optimal therapeutic window. Everolimus has an interpatient
pharmacokinetic variability up to 36–45% and shows dose
proportional pharmacokinetics over the range of 5 to 10 mg
once daily [5, 9, 13–15]. Given the exposure-effectiveness
relationship, the narrow therapeutic index, the large
interpatient variability, and linear pharmacokinetics, it seems
important to guide everolimus dosing pharmacokinetically.
If TDM of everolimus is performed in patients with cancer,
sampling with DBS can bring many advantages over venous
sampling, as it is minimally invasive, simple, and flexible.
After adequate training and with clear instructions, patients
can perform DBS at home and sent their sample by regular
mail to the laboratory for analysis. Also, physicians may ben-
efit from the ease of the DBS sampling method, as it can
provide them with analysis results before patients visit the
outpatient clinic for their (routine) check-up [7]. As such,
DBS is a promising alternative to venous sampling and it
already has become increasingly common in other anticancer
drugs [16–19]. The use of DBS to predict venous whole-blood
(WB) everolimus concentration has been established for organ
transplantation patients, in which the administered dosage of
everolimus ismuch lower than in cancer patients [6, 7, 20, 21].
In patients with cancer, the agreement between everolimus
DBS concentrations and WB concentrations is yet unknown.
In order to enhance the implementation of DBS in clinical
practice, this is the first clinical validation study, in which
we aim to determine the agreement and the predictive perfor-
mance of DBS compared to WB to measure everolimus con-
centrations in patients with cancer.
Methods
Study population
The current study is an observational pharmacokinetic
study in patients aged > 18 years, treated with everoli-
mus for any type of solid tumor at the Radboud univer-
sity medical center (Radboudumc), an academic hospital
in the Netherlands. No exclusion criteria were set since
the study population intends to reflect a Breal-life^
group of patients with cancer treated with everolimus.
As such, the dose and duration of everolimus treatment
was not restricted for inclusion.
Sampling and everolimus concentration
Each patient was sampled in the outpatient clinic during their
routine follow-up, at one moment, while being on steady state
(i.e., treated for at least 7 days). Patients were asked not to take
everolimus at the day of the visit at home, but only directly
after obtaining the WB and DBS samples. Two drops of cap-
illary blood were sampled on the sampling paper in order to
create the DBS samples in duplicate. To establish whether the
difference in blood source (capillary vs. whole blood) is a
cause of variation, an additional DBS was made from a drop
of whole blood (DBSwb).
Since hematocrit might affect the quantification of everoli-
mus in DBS due to inhomogeneity of the droplet on the paper,
the hematocrit value of theWB samples was determined at the
day the venipuncture and DBS took place. All samples per
patient were collected within 10 min of each other by a ded-
icated physician.
Time after drug administration (interval between last dose
intake and sampling) and dosing scheme were documented to
estimate everolimus trough concentration (Ctrough), as de-
scribed by Wang et al. [22].
Bioanalysis
The DBS and DBSwb samples were visually inspected and
scored whether the spot size was adequately shaped and sized
for analysis. If both spots were of correct size, the average
concentration of the two samples was used. If both spots were
of incorrect size, these samples were not used for further anal-
ysis. After scoring of spot size, a 7.5-mm disk from the central
part of the blood spot was punched out from the sample paper.
Bioanalysis of the WB, DBS, and DBSwb samples was per-
formed using two validated ultra performance liquid
chromatography-tandem mass spectrometry (UPLC-MS/
MS) methods. One method was used for the analysis of WB
samples and another method was used to analyze the DBS and
DBSwb samples [23].
Statistical analysis
The Clinical and Laboratory Standards Institute advises to
study 40 samples for agreement analysis [24]. However,
as everolimus is measured in WB and therefore in the
same matrix as DBS and as no effect of hematocrit is
expected, the expected variation in DBS measurements
is smaller than in other DBS studies. Moreover, in trans-
plantation patients, good agreement of everolimus mea-
surement between DBS and whole blood has been shown
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previously [21]. Therefore, we performed a power analy-
sis for Bland-Altman analysis to determine the sample
size [25]. Assuming an expected mean of difference of
9%, with a standard deviation of 5% and a maximum
allowed difference of 25%, and α of 0.05 and power of
0.80, we required samples of 20 patients. Two extra pa-
tients were recruited for the risk of invalid samples.
To study the level of agreement between everolimus con-
centrations in DBS, DBSwb, and WB, Bland-Altman analysis
was performed [26]. In this analysis, we set limits of clinical
relevance on a 25% range around the ratio of the two mea-
surements. This range was chosen, as everolimus can be dose-
adjusted in steps of 25% of the total dose. Passing-Bablok
regression analysis was performed to detect constant and pro-
portional bias, by analyzing the intercept and the slope of the
regression line, respectively [27].
Furthermore, the DBS everolimus concentration was used
to predict the measured WB concentration. With Passing-
Bablok regression, the intercept and slope were determined
using the whole population while excluding the data of the
individual patient from whom the WB everolimus concentra-
tion is to be predicted. Subsequently, the intercept and slope
were used to predict the WB everolimus concentration, based
on the DBS concentration. This process was repeated for each
individual patient. For analyzing the predictive performance,
the following equations from the guideline of Sheiner and
Beal [28] were used.
For bias:
median prediction error ¼ median WBpred‐WBð Þ ð1Þ
median percentage prediction error MPPEð Þ
¼ median 100% WBpred‐WBð Þ WB½  ð2Þ
For imprecision:
root median squared prediction error RMSEð Þ
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
median
p
WBpred‐WBð Þ2 ð3Þ
median absolute percentage prediction error MAPEð Þ
¼ median 100% WBpred‐WBð Þ WBjj½  ð4Þ
Values of MPPE and MAPE of < 15% were considered ac-
ceptable. Overall predictive performance was measured by the
percentage of samples with an absolute percentage prediction
error of < 20%. We set the criterion that at least 67% of samples
should have a prediction error of < 20%, analogous to the criteria
for cross validation of the European Medicines Agency (EMA)
guideline on bioanalytical method validation [29].
All calculations were performed using Microsoft Office
Excel (Microsoft Inc., Redmond, WA) and add-in Analyse-it
statistics software, version 4.10.2 (Analyse-it Software, Ltd.,
Leeds, UK).
Results
Patients and everolimus concentrations
As planned, 22 patients were included, from June to
December 2015. WB, DBS, and DBSwb samples of 20 pa-
tients were included in the final analysis, since one set of
samples were lost and the duplicate DBS samples of one pa-
tient was insufficient for analysis. The population consisted of
11 patients with mBC and 9 patients with mRCC. The median
age at index date was 62.0 years (range 38–73) and the median
everolimus dose was 10 mg (range 5–17.5 mg). The median
hematocrit value of the WB samples was 0.35 L/L (range
0.25–0.45) (Table 1). The everolimus concentrations of the
20 analyzed samples ranged from 3.7 to 33.3 μg/L in DBS,
from 3.3 to 31.2 μg/L in DBSwb and from 3.6 to 28.5 μg/L in
WB. When the Ctrough concentrations were calculated for the
individual patients using the equation of Wang et al., 55% of
patients had a Ctrough concentration below 11.9 μg/L and 15%
a Ctrough concentration above 26.3 μg/L [22].
Agreement between DBS, DBSwb, and WB everolimus
concentrations
Bland-Altman analysis was used to determine the level of
agreement between DBS, DBSwb, and WB everolimus con-
centrations. The Bland-Altman plot with 95% limits of agree-
ment (LoA) showed a small and balanced spread of relative
differences between DBS andWB everolimus concentrations,
with a mean ratio of everolimusWB to DBS concentrations of
0.90 (95% LoA 0.71–1.08). Only 1/20 (5%) of values fell
outside the limits of agreement and outside the limits of clin-
ical relevance (Fig. 1). Using Passing-Bablok regression anal-
ysis, a strong linear relationship was found between both
methods, with a correlation coefficient of r = 0.97, thus
explaining 95% of the variance (r2 = 0.95). No significant
constant bias was found, with an intercept close to zero (inter-
cept estimate 0.02 μg/L; 95% CI − 0.93–1.35), and only a
small proportional bias (slope estimate 0.89; 95% CI 0.76–
0.99) (Fig. 2).
Agreement between DBSwb and WB everolimus concen-
trations was comparable to the results of the DBS and WB
analysis. Bland-Altman analysis showed a mean ratio of
everolimus DBSwb concentrations to WB concentrations of
0.92 (95% LoA 0.79–1.05). Passing-Bablok regression
showed a coefficient of determination r2 = 0.98, no constant
bias (intercept − 0.17 μg/L; 95% CI − 1.37–0.51), and no
proportional bias (slope estimate 0.93; 95% CI 0.87–1.04).
Everolimus concentrations of DBS and DBSwb were simi-
lar, as the Bland-Altman plot showed a mean ratio of nearly 1
(mean ratio 0.98; 95% LoA 0.82–1.13). The Passing-Bablok
regression of the two DBS sampling methods showed a coef-
ficient of determination r2 = 0.97, no constant bias (intercept
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0.46 μg/L; 95% CI − 0.71–2.40) and no proportional bias
(slope estimate, 0.93; 95% CI 0.80–1.03).
Predictive performance of predicted everolimus WB
concentrations compared with measured WB
Based on the DBS concentrations and using the intercept and
slope, everolimus WB concentrations were predicted. The to-
tal error of this prediction is determined by bias (average dif-
ference between estimator and true value) and imprecision
(variance of the estimator). Bias between the predicted and
the measured everolimus concentration was negligible, with
median absolute difference as measured by MPE of only
0.015 μg/L, and median relative difference as measured by
MPPE of 0.035%. The imprecision of the predicted concen-
tration was small, with RSME of 0.76 μg/L and median ab-
solute percentage prediction error (MAPE) of 6.1%. These
values are well within the acceptable limits of 15%. Overall
predictive performance was good, as 90% of samples had an
absolute percentage prediction error of < 20% (Fig. 3), which
fell within the criterion of at least 67% of samples [29].
Discussion
In this study, we have shown that the agreement of DBS with
WB concentration measurements of everolimus in patients
with cancer is very high over the entire concentration range.
With DBS, results of 95% of samples fell within the limits of
clinical significance, which would thereby lead to the same
dosing advice as when WB measurement was used. The pre-
dictive performance of DBS was excellent, with negligible
bias and small imprecision and good overall predictive perfor-
mance, satisfying the EMA criteria for cross validation [29,
Fig. 1 Bland-Altman plot of ratio
between WB and DBS
everolimus concentrations versus
mean everolimus concentration
Fig. 2 Passing-Bablok plot of everolimus concentrations from DBS and
WB
Table 1 Baseline characteristics of patients
Baseline characteristics n = 20
Age (years) 62 (38–73)
Sex (number (%))
Male 8 (40%)
Female 12 (60%)
Weight (kg) 72.4 (48.5–90.2)
Hematocrit (L/L) 0.35 (0.25–0.45)
Everolimus daily dose (mg) 10.0 (5.0–17.5)
Tumor type (number (%))
Breast cancer 11 (55%)
Renal cell carcinoma 9 (45%)
Data are median (range), unless stated otherwise
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30]. Consequently, in view of the high agreement and excel-
lent predictive performance, DBS is a valid method as a prac-
tical alternative for venous sampling to measure everolimus
concentrations in patients with cancer. As such, these results
confirm the results of a DBS validation study of everolimus in
55 transplant patients, where a similar slope and a somewhat
larger intercept was found [21].
DBSwb was determined in order to discriminate influences
of the blood drop collection methods (capillary vs. whole
blood) and material (filter paper vs. EDTA tube). As DBS
and DBSwb everolimus concentrations were nearly similar, it
can be concluded that collection of blood by finger prick does
not affect concentration measurements of everolimus.
Albeit not significantly, DBS and DBSwb did show consis-
tently higher everolimus concentrations compared to measur-
ing everolimus inWB. Everolimus is strongly bound to eryth-
rocytes (approximately 85% at the blood concentration range
of 5–100 μg/L) [31, 32], and we speculate that this fraction
can have a higher concentration at the center of the punch of
the sampling paper. When hematocrit levels are low (≤ 0.20 L/
L), chromatographic effects can play a role, resulting in inac-
curately lower everolimus concentration measurements [33].
Especially DBS samples with high everolimus concentrations
(> 20 μg/L) in combination with low hematocrit can provide
inaccurate lower results [21, 34]. As hematocrit levels were ≥
0.25 L/L for all patients, the impact of hematocrit on everoli-
mus concentration measurement was not an issue in the pop-
ulation we investigated. However, awareness should be in
place for everolimus measurements in patients with a hemat-
ocrit below 0.20 L/L. The collection of blood spots by volu-
metric absorptive microsampling is an alternative for DBS
sampling that might overcome this issue, as it enables the
collection of an accurate blood volume, independently of he-
matocrit levels [35].
It is important to note certain limitations of this study. First,
the finger prick sampling was performed by a dedicated phy-
sician at the hospital, and since this situation does not reflect
the at-home oncology sampling setting, the results cannot be
extrapolated without further validation. Therefore, we recom-
mend future studies to perform a validation of clinical utility
with DBS cards sampled by patients themselves. However, we
expect at-home sampling to be feasible when clear instruc-
tions and adequate training are provided, since previous liter-
ature has shown that 86 to 98% of the DBS samples obtained
from patients were suitable for analysis [36–38]. Second, the
number of analyzed DBSwas relatively small. A smaller sam-
ple size leads to a wider confidence interval, resulting in a
decreased power to detect a difference between two methods.
However, this sample size is comparable to the sample size in
other studies with DBS and oral anticancer agents [16, 39],
while the agreement between DBS withWB for everolimus is
markedly better than for other anticancer drugs, such as
pazopanib and nilotinib [16, 39]. DBS shows a relatively high
performance to measure everolimus concentrations, when
compared to the performance of DBS for measuring other
drugs. This can partially be explained as everolimus is mea-
sured in WB instead of plasma, and therefore has the same
matrix as DBS.Moreover, good agreement of DBS and whole
blood has been shown for everolimus in transplantation pa-
tients [21]. Therefore, we considered it appropriate to base our
sample size on a power calculation using previously obtained
data in transplantation patients treated with everolimus for our
assumptions. This deems to be a legitimate approach, since
our data indeed show highly similar results to the previous
independently performed study. Third, only trough levels
were analyzed. This did not lead to restrictions, however, as
a wide range of everolimus concentrations were obtained.
In summary, it can be concluded that this is the first study
that demonstrates the clinical validity of DBS sampling for
analysis of everolimus concentration in patients with cancer.
Measuring everolimus concentrations in patients with cancer
is particularly important to identify patients with very low or
high everolimus concentrations. In our study 70% of our pa-
tients had extrapolated everolimus trough concentrations that
fell outside the proposed therapeutic window. In these pa-
tients, it is likely that dose adjustments can improve effective-
ness or prevent toxicity. DBS is a patient-friendly and practical
alternative for WB concentration measurements and in this
study has shown to be accurate for the goal to individualize
everolimus therapy in cancer patients. Implementation of stan-
dard everolimus DBS measurement early after start of treat-
ment has the potential to improve clinical outcomes for pa-
tients with cancer treated with everolimus.
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